KR20210149163A - 자가면역 질환의 치료를 위한 헥사하이드로-1H-피라지노[1,2-a]피라진 화합물 - Google Patents

자가면역 질환의 치료를 위한 헥사하이드로-1H-피라지노[1,2-a]피라진 화합물 Download PDF

Info

Publication number
KR20210149163A
KR20210149163A KR1020217036391A KR20217036391A KR20210149163A KR 20210149163 A KR20210149163 A KR 20210149163A KR 1020217036391 A KR1020217036391 A KR 1020217036391A KR 20217036391 A KR20217036391 A KR 20217036391A KR 20210149163 A KR20210149163 A KR 20210149163A
Authority
KR
South Korea
Prior art keywords
methyl
hexahydro
pyrazin
carbonitrile
pyrazino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217036391A
Other languages
English (en)
Korean (ko)
Inventor
웨이 주
지웨이 장
지센 장
홍 션
용푸 리우
야페이 리우
하이시아 리우
부위 코우
파비안 데이
루에 다이
리누오 주
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20210149163A publication Critical patent/KR20210149163A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217036391A 2019-04-09 2020-04-07 자가면역 질환의 치료를 위한 헥사하이드로-1H-피라지노[1,2-a]피라진 화합물 Withdrawn KR20210149163A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/081900 2019-04-09
CN2019081900 2019-04-09
CNPCT/CN2019/121598 2019-11-28
CN2019121598 2019-11-28
CN2020078225 2020-03-06
CNPCT/CN2020/078225 2020-03-06
PCT/EP2020/059831 WO2020207991A1 (en) 2019-04-09 2020-04-07 Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease

Publications (1)

Publication Number Publication Date
KR20210149163A true KR20210149163A (ko) 2021-12-08

Family

ID=70228042

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036391A Withdrawn KR20210149163A (ko) 2019-04-09 2020-04-07 자가면역 질환의 치료를 위한 헥사하이드로-1H-피라지노[1,2-a]피라진 화합물

Country Status (19)

Country Link
US (1) US20220340597A1 (https=)
EP (1) EP3953356B1 (https=)
JP (1) JP7692838B2 (https=)
KR (1) KR20210149163A (https=)
CN (1) CN113710672B (https=)
AU (1) AU2020272467A1 (https=)
BR (1) BR112021020297A2 (https=)
CA (1) CA3135129A1 (https=)
CL (1) CL2021002621A1 (https=)
CO (1) CO2021013166A2 (https=)
CR (1) CR20210513A (https=)
IL (1) IL286870A (https=)
MA (1) MA55594A (https=)
MX (1) MX2021012223A (https=)
PE (1) PE20212178A1 (https=)
PH (1) PH12021552533A1 (https=)
SG (1) SG11202110401WA (https=)
TW (1) TW202104230A (https=)
WO (1) WO2020207991A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021084022A1 (en) * 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728959B (zh) * 2019-11-12 2024-11-12 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢吡嗪并[1,2-b]异喹啉化合物
US12503471B2 (en) 2019-11-19 2025-12-23 Hoffmann-La Roche Inc. Triazatricycle compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
KR20220122637A (ko) 2019-11-28 2022-09-02 바이엘 악티엔게젤샤프트 면역 활성화를 위한 dgk알파 억제제로서의 치환된 아미노퀴놀론
WO2021110614A1 (en) * 2019-12-03 2021-06-10 F. Hoffmann-La Roche Ag HYDROPYRIDO[1,2-α]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
US20240317735A1 (en) * 2020-07-14 2024-09-26 Hoffmann-La Roche Inc. Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562201B (zh) * 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
RS56747B1 (sr) 2012-09-14 2018-03-30 Hoffmann La Roche Pirazol derivati karboksamida kao taar modulatori za upotrebu u lečenju nekoliko poremećaja, kao što su depresija, dijabetes i parkinsonova bolest
CN105992766A (zh) * 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
CA3005766A1 (en) 2015-12-17 2017-06-22 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
EP3807271A1 (en) * 2018-06-13 2021-04-21 F. Hoffmann-La Roche AG Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP2022501401A (ja) * 2018-09-27 2022-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 自己免疫疾患の治療のためのヘテロシクリル化合物

Also Published As

Publication number Publication date
PH12021552533A1 (en) 2022-06-20
CN113710672A (zh) 2021-11-26
AU2020272467A1 (en) 2021-10-14
EP3953356A1 (en) 2022-02-16
CO2021013166A2 (es) 2021-12-10
SG11202110401WA (en) 2021-10-28
CR20210513A (es) 2021-11-02
IL286870A (en) 2021-10-31
TW202104230A (zh) 2021-02-01
WO2020207991A1 (en) 2020-10-15
BR112021020297A2 (pt) 2021-12-14
CA3135129A1 (en) 2020-10-15
PE20212178A1 (es) 2021-11-09
CN113710672B (zh) 2025-01-03
EP3953356B1 (en) 2023-07-26
US20220340597A1 (en) 2022-10-27
MA55594A (fr) 2022-02-16
JP2022527588A (ja) 2022-06-02
JP7692838B2 (ja) 2025-06-16
CL2021002621A1 (es) 2022-05-13
MX2021012223A (es) 2021-11-03
EP3953356C0 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
JP7692838B2 (ja) 自己免疫疾患の治療のためのヘキサヒドロ－１Ｈ－ピラジノ［１，２－ａ］ピラジン化合物
EP3802539B1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
US12486273B2 (en) Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
WO2019238629A1 (en) Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
TW202024065A (zh) 用於治療自體免疫疾病之雜環基化合物
KR20260040007A (ko) 자가면역질환 치료를 위한 거대고리
EP4051387B1 (en) Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
EP3623369B1 (en) Novel morpholinyl amine compounds for the treatment of autoimmune disease
US12503471B2 (en) Triazatricycle compounds for the treatment of autoimmune disease
HK40055574B (zh) 用於治疗自身免疫性疾病的六氢-1h-吡嗪幷[1，2- a]吡嗪化合物
HK40055574A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease
CA3285578A1 (en) New e3 ubiquitin ligase ligand, protein degradation agent and use thereof
HK40068905B (zh) 用於治疗自身免疫性疾病的氢吡嗪并[1，2-d][1，4]二氮杂䓬化合物
HK40037002B (zh) 用於治疗自身免疫性疾病的四氢-1h-吡嗪并[2，1-a]异吲哚基喹啉化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000